Influence of tamoxifen on carotid intima-media thickness in postmenopausal women

Circulation

Volumn 106, Issue 23, 2002, Pages 2925-2929

  Simon, T ^a   Boutouyrie, P ^b   Simon, J M ^c   Laloux, B ^b   Tournigand, C ^a   Tropeano, A I ^b   Laurent, S ^b   Jaillon, P ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Atherosclerosis; Carotid arteries; Menopause; Prevention; Selective estrogen receptor modulators

Indexed keywords

SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; AGED; AGING; ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; BREAST CARCINOMA; CALCULATION; CARDIOVASCULAR RISK; COMMON CAROTID ARTERY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PULSE PRESSURE; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; TONOMETRY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CAROTID ARTERIES; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS; SAMPLE SIZE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TUNICA INTIMA; TUNICA MEDIA;

EID: 0037016060     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000041044.93571.CA     Document Type: Article

References (34)

1. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
2. Simon T, Jaillon P. Hormone replacement therapy in postmenopausal women at cardiovascular risk: Epidemiology and clinical trials. Eur Heart J. 2000;2:G2-G6.
3. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
4. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-1249.
5. Writing group for the WHI investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
6. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609-1618.
7. Clarke SC, Schofield PM, Grace AA, et al. Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation. 2001;103:1497-1502.
8. Love RR, Wiebe DA, Feyzi JM, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 1994;86:1534-1539.
9. Grey AB, Stapleton JP, Evans MC, et al. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab. 1995;80:3191-3195.
10. Cushman M, Costantino JP, Tracy RP, et al. Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol. 2001;21:255-261.
11. Cattaneo M, Baglietto L, Zighetti ML, et al. Tamoxifen reduces plasma homocysteine levels in healthy women. Br J Cancer. 1998;77:2264-2266.
12. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen: The Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1993;85:1398-1406.
13. Costantino JP, Kuller LH, Ives DG, et al. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst. 1997;89:776-782.
14. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial: The Scottish Cancer Trials Breast Group. BMJ. 1995;311:977-980.
15. Reis SE, Costantino JP, Wickerham DL, et al. Cardiovascular effects of tamoxifen in women with and without heart disease: Breast cancer prevention trial: National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst. 2001;93:16-21.
16. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14-22.
17. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262-269.
18. McGrath BP, Liang YL, Teede H, et al. Age-related deterioration in arterial structure and function in postmenopausal women: Impact of hormone replacement therapy. Arterioscler Thromb Vasc Biol. 1998;18:1149-1156.
19. Westendorp IC, In't Veld BA, Bots ML, et al. Hormone replacement therapy and intima-media thickness of the common carotid artery: The Rotterdam study. Stroke. 1999;30:2562-2567.
20. Espeland MA, Applegate W, Furberg CD, et al. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women: Asymptomatic Carotid Atherosclerosis Progression Study. Am J Epidemiol. 1995;142:1011-1019.
21. Hoddis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135:939-953.
22. Boutouyrie P, Bussy C, Hayos D, et al. Local pulse pressure and regression of arterial wall hypertrophy during long term antihypertensive treatment. Circulation. 2000;101:2601-2606.
23. Boutouyrie P, Bussy C, Lacolley P, et al. Association between local pulse pressure, mean blood pressure and arterial remodeling. Circulation. 1999;100:1387-1393.
24. Gruber CJ, Tschugguel W, Schneeberger C, et al. Production and actions of estrogens. N Engl J Med. 2002;346:343-352.
25. Smith SC Jr, Greenland P, Grundy SM. AHA conference proceedings: Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: Executive summary. Circulation. 2000;101:111-116.
26. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445-1551.
27. Herrington DM, Pusser BE, Riley WA, et al. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women. Arterioscler Thromb Vasc Biol. 2000;20:1606-1612.
28. Williams JK, Wagner JD, Li Z, et al. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary atherosclerosis in monkeys. Arterioscler Thromb Vasc Biol. 1997;17:403-408.
29. Van Dijk MA, Hart AA, Van't Veer LJ. Differences in estrogen receptor alpha variant messenger RNAs between normal human breast tissue and primary breast carcinomas. Cancer Res. 2000;60:530-533.
30. Karas RH, Hodgin JB, Kwoun M, et al. Estrogen inhibits the vascular injury response in estrogen receptor β-deficient female mice. Proc Natl Acad Sci U S A. 1999;96:15133-15136.
31. Herrrington DM, Howard TD, Hawkins GA, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002;346:967-974.
32. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999;100:717-722.
33. Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol. 2000;36:1797-1802.
34. Barret-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287:847-857.